UPDATE: OPKO Health (OPK) Easily Tops Q3 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
OPKO Announces Third Quarter Financial and Operating Results
November 9, 2015 4:13 PM ESTConsolidated Revenue Increased to $143.0 Million From $19.8 million for the Three Months Ended September 30, 2015, and Increased to $215.5 Million from $65.6 Million for the Nine Months Ended September 30, 2015 Closed Acquisition of Bio-Reference Laboratories on August 20, 2015 Announced Genomics Collaboration with Vanderbilt University School of Medicine 4Kscore® Blood Test to Identify Risk of Aggressive Prostate Cancer Included in the National Comprehensive Cancer Network Guidelines for Cancer Early Detection RayaldeeTM New Drug Application (NDA) Accepted by FDA; Expected PDUFA Date is March 29, 2016... More
